Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (437)	4/28/2000 8:59:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 804

I listened to part of their CC (available on the web). Pretty upbeat call, although for some reason they discouraged analysts (Mike King in particular) from upping their T sales projections for the remainder of the year (but with a caveat that publication of good study results could change this). Lots of talk about how their large cash position now makes them a "different company." (true) Sounds like there will be lots of T papers at ASCO and ASH. Said they take the FDA warning "very seriously", but downplayed any impact on sales or basic practices at all. Lots of discussion about SelCids, most of which I missed. I am always scared, however, when I hear talk of a follow-on compound with "1000 times the potency." Celgro was discussed briefly - they said it's a non-core smaller part of the business now, but claimed it to be progressing nicely. No specifics on the claimed progress, though. It's now in a separate building - sounds to me like they'll try to spin it off or sell it. Anyhow I bought a little more after the dip from the warning letter, rebuilding my position a little after lightening up some at much higher levels. Peter